Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Motor impairments in children: More than just the clumsy child

Developmental co-ordination disorder is a motor skill disorder that affects an estimated 5-6% of children but lacks recognition and understanding, leading to under-diagnosis

Research

Predicting language difficulties in middle childhood from early developmental milestones: A comparison of traditional regression and machine learning techniques

The current study provides preliminary evidence that machine learning algorithms provide equivalent predictive accuracy to traditional methods for language difficulties in middle childhood

Research

Exploring quality of life of children with cerebral palsy and intellectual disability: What are the important domains of life?

An estimated half of all children with cerebral palsy also have comorbid intellectual disability, the domains of QOL for these children are not well understood

Research

A randomised controlled trial of an iPad-based application to complement early behavioural intervention in Autism Spectrum Disorder

Technology-based interventions may provide a relatively low-cost addition to existing therapist-delivered interventions for children with ASD

Research

Elizabeth Usher Memorial Lecture: Rethinking the clinical pathway for autism spectrum disorder and challenging the status quo

The aim of the paper is to outline the future of early identification and intervention of ASD and the research goals to be addressed to achieve this vision.

Research

Protective benefit of predominant breastfeeding against otitis media may be limited to early childhood: results from a prospective birth cohort study

Our findings are in line with a number of epidemiological studies which show a positive association between breastfeeding and OM in early childhood

Research

Co-design of the neurodevelopment assessment scale

Neurodevelopmental disorders (NDDs) have high comorbidity rates and shared etiology. Nevertheless, NDD assessment is diagnosis-driven and focuses on symptom profiles of individual disorders, which hinders diagnosis and treatment. There is also no evidence-based, standardized transdiagnostic approach currently available to provide a full clinical picture of individuals with NDDs. The pressing need for transdiagnostic assessment led to the development of the Neurodevelopment Assessment Scale.

Research

Sex-Specific Effects of Birth Weight on Longitudinal Behavioral Outcomes: A Mendelian Randomization Approach Using Polygenic Scores

It is unclear whether sex differences in behavior arising from birth weight (BW) are genuine because of the cross-sectional nature and potential confounding in previous studies. We aimed to test whether sex differences associated with BW phenotype were reproducible using a Mendelian randomization approach, i.e., association between polygenic score (PGS) for BW and behavior outcomes across childhood and adolescence. 

Research

Low-intensity parent- and clinician-delivered support for young autistic children in Aotearoa New Zealand: a randomised controlled trial

Aotearoa New Zealand does not provide publicly-funded intensive autism support. While parent-mediated supports are promising, children and families may also benefit from direct clinician support. We tested the efficacy of a low-intensity programme involving parent- and clinician-delivered support for autistic children.

Research

The use of psychotropic medications in autistic individuals (21 years and younger) in Western Australia: A preliminary investigation

Prescriptions and use of medications to treat mental health conditions in young autistic populations are inconsistent worldwide. This makes it hard to compare findings from international studies to the Australian autistic population, where there are limited relevant studies. Apart from risperidone, there are no other medications specified for direct use in autistic persons. This study aims to gain initial broad understanding of the use of medications, commonly prescribed for mental health conditions, specifically by autistics under the age of 21 years.